Product Description
ʻO Vardenafil Hydrochloride Puka wikiō-AASraw
maka ʻO Vardenafil HCL Nā Kiʻi Kumu Paʻa
| Name: | ʻO Vardenafil hydrochloride (Levitra) ka lepo |
| CAS: | 224785-91-5 |
| Kaulike Molecular: | C22H19N3O4 |
| Kaumaha Molecular: | 389.4 |
| Wahi Manaʻo: | 298-300 ° C |
| Hōʻoia Kōkua: | 20ºC |
| kala like 'ole: | Ka Lulu Maʻemaʻe |
He aha ka Vardenafil hydrochloride Powder?
ʻO Vardenafil hydrochloride pauka, i kapa ʻia ʻo vardenafil HCL pauka, ʻo ia kekahi o ka enzyme phosphodiesterase type 5 (PDE5) inhibitors. ʻO kēia enzyme ke kuleana no ka hoʻohaʻahaʻa ʻana i ka cyclic guanosine monophosphate (cGMP), kahi mole e hana koʻikoʻi i ke kaʻina hana erectile.
I ka wā o ka moe kolohe, hoʻokuʻu ʻia ka nitric oxide i loko o ke kino erectile o ka penis (corpus cavernosum), a laila hoʻoulu i ka enzyme guanylate cyclase. ʻO kēia mau ʻiʻo e hiki ai ke kahe hou aku ke koko i loko o ka penis, e alakaʻi ana i kahi kūkulu.
Ma ke kāohi ʻana i ka PDE5, AASraw vardenafil hydrochloride ka pauka e pale i ka haki ʻana o cGMP, pēlā e mālama ai i nā pae kiʻekiʻe o kēia mole a hoʻolōʻihi i kona hopena.
Pehea e hana ai ka Vardenafil hydrochloride Powder?
ʻO Vardenafil hydrochloride pauka e hana ma ke ʻano he mea hoʻopale koho o kahi enzyme i kapa ʻia ʻo phosphodiesterase type 5 (PDE5).
①Hoʻoulu ka hoʻoulu ʻana i ka wahine i ka hoʻokuʻu ʻana o ka nitric oxide i loko o ka corpus cavernosum, kahi ʻāpana o ka penis.
②Hoʻomaka kēia nitric oxide i kahi enzyme i kapa ʻia ʻo guanylate cyclase e hoʻololi i ka guanosine triphosphate (GTP) i cyclic guanosine monophosphate (cGMP).
③ ʻO ka cGMP ka mea e hoʻomaha ai nā ʻiʻo maʻemaʻe i loko o ka corpus cavernosum, kahi e hiki ai i nā kīʻaha koko ke pālahalaha.
④ ʻO ka hoʻonui ʻana o nā kīʻaha koko e hoʻonui i ke kahe o ke koko i loko o ka penis, e alakaʻi ana i kahi kūkulu.
⑤Ma keʻano maʻamau, hoʻopau ka enzyme PDE5 i ka cGMP, e hoʻopau ana i ke kūkuluʻana. Hanaʻo Vardenafil hydrochloride ma ke kāohiʻana i ka hana a PDE5, pēlā eʻae ai i ka cGMP e noho lōʻihi a hoʻolōʻihi i ke kūkuluʻana.
⑥ ʻO ka hope loa, hoʻonui a hoʻomau ka vardenafil hydrochloride i ke kaʻina hana ola e alakaʻi i kahi kūkulu i pane i ka hoʻoulu ʻana i ka wahine.
He mea nui e hoʻomaopopo i ka vardenafil hydrochloride ʻaʻole ia e hoʻokumu i kahi kūkulu pololei. Akā, hoʻonui ia i ka pane kūlohelohe o ke kino i ka hoʻoulu ʻana. makahiki.
ʻO Vardenafil VS.Avanafil VS.Tadalafil VS.Sildenafil
ʻO nā mea hoʻopiʻi PDE5 maʻamau ʻehā ma ka mākeke ʻo sildenafil,hoʻopālaha,vardenafil, a me avanafil.ʻO kēia mau lāʻau lapaʻau ʻehā he mau mea hoʻopaneʻe PDE5 a ʻo ia ka lālani mua o ka mālama ʻana no ED. Akā naʻe, ʻokoʻa nā ʻano molekele kemika o kēia mau lāʻau lapaʻau ʻehā, ka hopena i nā hana kemika a me ke kino. ʻokoʻa ka excretion i ke kino, e like me kā lākou hopena curative.
| PDE5 Kāohi | Hoomaka o ka hana | Tmax (h) | Cmax (ng/ml) | T1/2 (h) | Ka lōʻihi (h) | ʻO nā hana ʻino nui |
| ʻO Sildenafil | 30min-1h | 0.8-1 | 560 | 2.6-3.7 | 4 | ʻO ka ʻeha o ke poʻo, ka ʻili ʻana o ka maka, ka ʻai ʻana, ka ʻāʻī ʻana o ka ihu, ka ʻūhā, ka ʻike ʻole |
| Kalaupapa | 15 min | 0.9 | 200 | 3.9 | 8 | ʻO ka ʻeha o ke poʻo, ka ʻili ʻana o ka maka, ka ʻai ʻana, ka ʻāʻī ʻana o ka ihu, ka ʻūhā, ka ʻike ʻole |
| ʻO Tadalafil | 1h | 2 | 378 | 17.5 | 36 | ʻO ka ʻeha o ke poʻo, ka ʻili ʻana o ka maka, ka ʻai ʻana, ka ʻāʻī ʻana o ka ihu, ka ʻūlū, ʻaʻohe mea ʻike ʻole |
| Avanafil | 10-15 min | / | > 1000 | 3-5 | 6-8 | ʻO ka ʻeha poʻo, ka ʻili ʻana o ka maka, ka ʻai ʻana, ka ʻāʻī ʻana o ka ihu, ka ʻūhā (ʻaʻole i hoʻohālikelike ʻia me nā mea ʻē aʻe) |
'Ōlelo Aʻo:
Tmax = ka manawa e hiki ai ke kiʻekiʻe o ka plasma concentration
ʻO Cmax = ka nui o ka plasma koko
T1/2 = hapalua ola
Hōʻuluʻulu kēia papaʻaina i nāʻano pharmacokinetic o nā mea hoʻopiʻi PDE5ʻehā i kūkākūkāʻia. He mea nui i nā mea mālama ola ke noʻonoʻo i kēia mauʻokoʻa i ka wā e kuhikuhi ai i kēia mau lāʻau lapaʻau, a pono e hoʻohana mau nā maʻi i kēia mau lāʻau ma lalo o ka nānāʻana o ke kauka. ʻO ka mea kūʻai hilinaʻi e like me AASraw e hōʻoiaʻiʻo ana e loaʻa iāʻoe kahi huahana o ka maikaʻi a me ka maʻemaʻe.AASraw , ma keʻano he mea hoʻolakoʻoihana vardenafil hcl pauka, hiki ke hoʻolako i ka vardenafil hydrochloride pauka me ke kūlana kiʻekiʻe ma ka honua holoʻokoʻa.
Pehea e koho ai i ka PDE5 inhibitors?
ʻO ke koho ʻana i ka PDE5 inhibitor pono hiki ke hilinaʻi i nā ʻano kumu like ʻole, e like me ke olakino holoʻokoʻa o ka mea maʻi, ke kū ʻana o nā kūlana ʻē aʻe, ko lākou nohona, a me kā lākou pane pilikino i ka lāʻau. e kūkākūkā mau me kahi mea mālama ola e hana i ka koho maikaʻi loa no nā pono pilikino.
| Kūlana hoʻomanawanui | Paipai ʻia ʻo PDE5 Inhibitor | kumu |
| Makemake i ka manawa hoʻomaka wikiwiki | Avanafil | ʻO ka hoʻomaka wikiwiki loa ma waena o ka PDE5 inhibitors |
| ʻO nā makahiki waena a me nā ʻelemakule me ED a me nā maʻi maʻi (hypertension, hyperlipidemia) | ʻO Sildenafil | ʻO nā ʻāpana pharmacokinetic maʻamau, hoʻemi i ka hoʻoulu ʻana i ke kino |
| ʻO ka makahiki waena a me ka ʻelemakule me ED a me ka vascular endothelial dysfunction (egdiabetes) | ʻO Tadalafil | ʻO ka lōʻihi o ka hana, hiki ke hoʻomaikaʻi i ka hana endothelial vascular a me nā hōʻailona urinary tract i ka manawa |
| ʻO ka makahiki waena a me ka ʻelemakule me ED, ʻaʻohe maʻi vascular | Kalaupapa | He hopena maʻalahi, hoʻomaka wikiwiki, bioavailability haʻahaʻa, liʻiliʻi nā hopena ʻino |
| ʻO ka makahiki waena a me ka ʻelemakule me ED, vascular endothelial dysfunction, sildenafil ineffective | Avanafil | ʻO ke koko kiʻekiʻe, ka hopena ikaika |
| ʻO nā ʻōpio a me nā makahiki waena me ED, ʻaʻohe etiology kūlohelohe | ʻO Sildenafil | Pono no ED ma muli o nā kumu noʻonoʻo |
| ʻO ka hana ʻike ʻole a me ED | ʻO Tadalafil | ʻAʻohe mea ʻikeʻole i waena o nā hopena ʻino |
| ʻO ka makemake o ka lāʻau lapaʻau postprandial | ʻO Avanafil, Vardenafil | ʻAʻole maʻalahi ka hoʻopili ʻana e ka meaʻai |
Nota: Hāʻawi ʻia kēia ʻike e pili ana i nā mea paʻa PDE5 no nā kumu ʻike ākea wale nō a ʻaʻole ia he ʻōlelo aʻoaʻo olakino. lawe ʻia, a me ke ʻano kikoʻī a me ke koʻikoʻi o ka erectile dysfunction. ʻOiai hiki i kēia mau lāʻau lapaʻau ke hana maikaʻi i ka mālama ʻana i ka erectile dysfunction, loaʻa iā lākou nā hopena ʻaoʻao a me nā pilikia, a ʻaʻole kūpono ia no kēlā me kēia. PDE5 inhibitors, e alakaʻi ana i nā hopena koʻikoʻi koʻikoʻi.
ʻO ka dosage a me ka hoʻokele ʻana o Vardenafil hydrochloride Powder no ka kuhikuhi
Hiki keʻano likeʻole keʻano o ka vardenafil HCL pauka ma muli o ke olakino o kēlā me kēia kanaka, ka pane i ka lāʻau lapaʻau, a me nā lāʻau'ē aʻe a lākou e lawe ai.
①hae dose no erectile dysfunction
ʻO ka 10 mg ka hoʻomaka ʻana o ka vardenafil, lawe waha ʻia ma kahi o 60 mau minuke ma mua o ka hana moekolohe. Hiki ke hoʻonui ʻia ka nui i ka 20 mg a i ʻole e hoʻemi ʻia i ka 5 mg, e pili ana i ka pono a me ka hoʻomanawanui. o ka la.
②ʻO nā maʻi me mʻoluʻolu hepatic ihōʻemi
No nā poʻe maʻi me ka haʻahaʻa haʻahaʻa haʻahaʻa (Child-Pugh B), ua ʻōlelo ʻia kahi ʻano hoʻomaka o 5 mg o vardenafil.
③ʻO nā maʻi me smau loa renal ihōʻemi
No nā poʻe maʻi me ka hōʻino o ka renal koʻikoʻi (CLcr <30 mL / min), hoʻomaka ka 5 mg o vardenafil.
④Nā maʻi ma spapaʻaina alpha-bpale laka tlāʻau lapaʻau
ʻO ka hoʻomaka ʻana o ka vardenafil no ka poʻe maʻi e loaʻa ana i ka alpha-blocker therapy he 5 mg.
⑤ʻO nā maʻi me chui pū ʻana use o CYP3A4 inā mea pale
No nā poʻe maʻi e lawe ana i nā mea hoʻopaneʻe ikaika CYP3A4 (e like me ketoconazole, itraconazole, ritonavir, indinavir, saquinavir, a me atazanavir), ʻaʻole pono e hoʻonui ʻia ka nui mua o 5 mg vardenafil.
Notes
He mea nui e hoʻomaopopo i ka hoʻouluʻana i ka wahine no ka paneʻana i ka lāʻau. ka huahana e kōkua i ka hoʻokō ʻana i ka hopena maikaʻi loa no kāna hoʻohana i manaʻo ʻia. ʻO ka AASraw ka manaʻo e hoʻolako i ka vardenafil hcl pauka kiʻekiʻe ma ka honua holoʻokoʻa ma lalo o ke kānāwai CGMP.
Ma hea e kūʻai ai i ka Vardenafil hydrochloride Powder?
Hiki ke kūʻaiʻia ka Vardenafil hydrochloride pauka mai nā mea kūʻai pūnaewele likeʻole e kūʻai aku i nā mea hana lāʻau. huahana no nā noi olakino. E hōʻoia i ka mea kūʻai aku e hāʻawi i nā kikoʻī huahana a me nā palapala hōʻoia maikaʻi, e like me kahi palapala hōʻoia.
Inā ʻoe e ʻimi nei i kahi kumu hilinaʻi no ke kūʻai ʻana i ka pauka vardenafil,KANAKA hiki paha i kahi koho kūpono. ʻO AASraw kahi hui e hāʻawi ana i ka nui o nā mea waiwai lāʻau lapaʻau, me ka vardenafil pauka. Hoʻohana maʻamau ʻia kā lākou huahana e nā laboratories a me nā keʻena noiʻi no ka hoʻomohala ʻana a me ka hana ʻana i nā huahana olakino like ʻole.
maka ʻO Vardenafil HCL Hōʻike hoʻāʻo pauda-HNMR
He aha ka HNMR a He aha ka HNMR spectrum e haʻi aku iā ʻoe? ʻO H Nuclear Magnetic Resonance (NMR) spectroscopy kahi ʻenehana kemika analytical i hoʻohana ʻia i ka hoʻokele maikaʻi a me ka noiʻi no ka hoʻoholo ʻana i ka ʻike a me ka maʻemaʻe o kahi laʻana a me kona ʻano molekala. No ka laʻana, hiki i ka NMR ke hoʻokaʻawale i nā hui pū ʻia i ʻike ʻia. No nā pūhui i ʻike ʻole ʻia, hiki ke hoʻohana ʻia ka NMR e hoʻohālikelike i nā hale waihona puke spectral a i ʻole e kuhi pololei i ke ʻano kumu. Ke ʻike ʻia ke ʻano kumu, hiki ke hoʻohana ʻia ka NMR no ka hoʻoholo ʻana i ka conformation molecular i ka hopena a me ke aʻo ʻana i nā waiwai kino ma ka pae molekala e like me ka hoʻololi conformational, nā hoʻololi ʻana, ka solubility, a me ka diffusion.
Vardenafil Hydrochloride pauka (224785-91-5) -COA
Vardenafil Hydrochloride pauka (224785-91-5) -COA
Pehea e kūʻai ai i ka Vardenafil HCL Powder mai AASraw?
❶E hoʻokaʻaʻike mai iā mākou ma kā mākou ʻōnaehana nīnau leka uila, a i ʻole e waiho i kāu helu whatsapp iā mākou, e hoʻopili kā mākou mea kūʻai aku (CSR) me ʻoe i loko o 12 mau hola.
❷E hāʻawi mai iā mākou i kāu helu a me kāu helu wahi i nīnau ʻia.
❸Na kā mākou CSR e hāʻawi iā ʻoe i ka ʻōlelo, ka manawa uku, ka helu ʻimi, nā ala hoʻouna a me ka lā i manaʻo ʻia (ETA).
❹E uku ʻia a hoʻouna ʻia nā waiwai i loko o 12 mau hola.
❺ Loaʻa nā waiwai a hāʻawi i nā manaʻo.
Mea kākau o kēia ʻatikala:
Kauka Monique Ua puka 'o Hong mai ke Kula Nui o UK Imperial College London Faculty of Medicine
Mea kākau moʻolelo puke moʻolelo ʻepekema:
1. Hazem M. Abu Shawish
Keʻena Kemika, Koleke ʻEpekema, Ke Kulanui ʻo Al-Aqsa, Gaza, Palesetina
2. E. BISCHOFF
Mai ka Institute of Cardiovascular Research II, a me nā keʻena o ka noiʻi kemika, a me ka hoʻomohala ʻana i nā huahana a me nā Pharmacokinetics Preclinical, BAYER AG Pharmaceutical Business Group, Wuppertal, Kelemānia
3. MM Mabrouk
Keʻena o ka lāʻau lapaʻau analytical kemika, kumu o ka lāʻau lapaʻau, Tanta kulanui, Tanta, ʻAigupita
4. Engin Yurtcu
Obstetrics and Gynecology Department of Zekai Tahir Burak Women's Health and Research Hospital, Ankara, Turkey
5. Silvia Limoncella
Unit o Endocrinology, Keʻena o Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italia
ʻAʻole ʻae kēia kauka/ ʻepekema i ke kūʻai, kūʻai ʻana, a hoʻohana paha i kēia huahana no kekahi kumu. ʻAʻohe pili a pili ʻole ʻo Aasraw, i hōʻike ʻia a i ʻole, me kēia kauka. ʻO ke kumu o ka haʻi ʻana i kēia kauka, ʻo ia ka hoʻomaikaʻi, hoʻomaikaʻi a hoʻomaikaʻi i ka hana noiʻi a me ka hoʻomohala piha i hana ʻia e nā ʻepekema e hana nei i kēia mea.
Reference
[1] Aversa A, Pili M, Francomano D, Bruzziches R, Spera E, La Pera G, Spera G (Iulai 2009). "Nā hopena o ka hoʻokele vardenafil ma ka intravaginal ejaculatory latency time i nā kāne me ka ejaculation premature lōʻihi". Ka Palapala'Ōiwi Aupuni o kaʻIke. 21 (4):221–7.
[2] Nā Kula Lapaʻau (Glen L.Stimmel,D., a me Mary A.Gutierrez,Pharm.D.) a me nā lāʻau lapaʻau (Glen L.Stimmel,Pharm.D.), Kulanui o Kaleponi Hema, Los Angeles, Kaleponi. "Ke aʻoʻana i nā maʻi e pili ana i nā pilikia pili i ka wahine: Priapism i hoʻokomoʻia i ka lāʻau".Medscape.Retrieved 2010-12-06.
[3] "Hoʻomaʻamaʻa erectile dysfunction hou ʻo Staxyn i ʻae ʻia ma US.- Hoʻoponopono lāʻau lapaʻau". mail.2010-06-21. Waiho ʻia mai ka mea kumu ma 2012-04-06.
[4] Tucker J, Fischer T, Upjohn L, Mazzera D, Kumar M (ʻOkakopa 2018). "ʻO nā mea lāʻau lapaʻau ʻaʻole i ʻae ʻia i loko o nā meaʻai meaʻai i hui pū ʻia me nā ʻōlelo aʻo a ka US Food and Drug Administration". Ka Honua JAMA Open. 1(6):
[5] Lepor H, Lepor NE, Hill LA, Trohman RG (2008). "ʻO ka QT Interval a me ke koho ʻana o nā Alpha-Blockers no Benign Prostatic Hyperplasia". Nānā ma Urology. 10 (2):85–91.
